Human fibrinogen concentrate market to reach $2.9b by 2035

It is expected to grow at a CAGR of 11% within the forecast period.

The global human fibrinogen concentrate market is expected to reach $2.9b by 2035 at a compound annual growth rate (CAGR) of 11%.

A report by Allied Market Research revealed that the market is driven by an increase in global bleeding disorder incidences, necessitating the use of human fibrinogen concentrates, notably in critical surgical procedures.

Advancements in biotechnology have also contributed to the market’s demand amidst the development of more sophisticated formulations that emphasise enhanced efficacy and safety.

“Furthermore, the rise in awareness among healthcare practitioners and patients regarding the therapeutic advantages of fibrinogen concentrate is fostering its adoption, particularly within clinical settings,” The report said.

By end user, the hospital segment is projected to rise with an 11% CAGR during the forecast period.

According to Allied Market Research, the market is driven by a surge in the number of surgeries, leading to a rise in the adoption of surgical sealants such as human fibrinogen.

“For instance, there were approximately 294 million surgical procedures performed in 2022 globally as per the World Health Organisation (WHO) and the number is increasing by around 8-10% year on year,” The report added.